How This Israeli Biotech Could be a Threat to Celgene

Can-Fite Biopharma is an advanced clinical stage drug development company located in Israel.

Can-Fite is currently developing a psoriasis drug in Phase III trials which compares well to Otezla at weeks 24-32.

Celgene should buy Can-Fite in order to gain access to a couple of very promising candidates, and as an insurance policy for Otezla.

Back to news